Janux Therapeutics, Inc. Common Stock (JANX) Stock
Key stats
- Market cap
- $758.06M
- Price / Earnings ratio
- -7.4x
- EPS (TTM)
- -$1.59
- Volume
- Loading
- 52-week high
- $35.34
- 52-week low
- $11.59
Source: third-party data provider, as of November 13, 2026
Compare with JANX
Recent news

Janux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011 in Healthy Volunteers
Janux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011 in Healthy Volunteers
JANX

4 Prostate Cancer Drug Stocks to Watch During Awareness Month
4 Prostate Cancer Drug Stocks to Watch During Awareness Month
JANX

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013
JANX

JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know
JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know
JANX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 31.69
- MACD 12/26/9
- -0.91
- EMA 9 of MACD
- -0.32
- MACD histogram
- -0.59
- SMA 50
- $17.13
- Price below SMA 50
- EMA 50
- $16.66
- Price below EMA 50
- SMA 200
- $15.38
- Price below SMA 200
- EMA 200
- $16.28
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Janux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011 in Healthy Volunteers
Janux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011 in Healthy Volunteers
JANX

4 Prostate Cancer Drug Stocks to Watch During Awareness Month
4 Prostate Cancer Drug Stocks to Watch During Awareness Month
JANX

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013
JANX

JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know
JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know
JANX

Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates
JANX

Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
JANX

Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Know
Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Know
JANX

Here's Why You Should Add JANX Stock to Your Portfolio Now
Here's Why You Should Add JANX Stock to Your Portfolio Now
JANX

Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates
Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates
JANX

Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
JANX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Janux Therapeutics, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. David Alan Campbell Ph.D. | President, Co-Founder, CEO & Director | 1960 |
| Dr. Thomas Diraimondo Ph.D. | Chief Scientific Officer | 1986 |
| Ms. Janeen Doyle | Chief Corporate & Business Development Officer | 1978 |
| Mr. Matt Whitmire | Vice President of Finance | — |
| Ms. Maria Dobek | Vice President of Accounting | 1990 |
| Mr. Charles M. Winter | Chief Technical Officer | 1969 |
| Mr. James Pennington | General Counsel & Corporate Secretary | — |
| Ms. Mandie Forman-Sklansky | Head of Human Resources | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 31.69
- MACD 12/26/9
- -0.91
- EMA 9 of MACD
- -0.32
- MACD histogram
- -0.59
- SMA 50
- $17.13
- Price below SMA 50
- EMA 50
- $16.66
- Price below EMA 50
- SMA 200
- $15.38
- Price below SMA 200
- EMA 200
- $16.28
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $15.00
- Average
- $26.25
- High
- $40.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -16.1 | +27.8 | ||||||||||
| 2022 | -24.8 | +9.8 | -14.7 | -35.1 | +7.6 | +28.3 | +5.3 | -6.3 | +21.9 | +40.0 | -25.3 | -3.2 |
| 2023 | +58.4 | -17.7 | -27.1 | +23.9 | -24.3 | -1.9 | +14.0 | -16.9 | -8.4 | -32.4 | +36.0 | +18.7 |
| 2024 | -22.3 | +469.8 | -21.0 | +51.2 | -8.1 | -23.8 | -2.7 | +13.3 | +0.9 | +21.3 | -16.9 | +33.3 |
| 2025 | -18.3 | -21.8 | -15.2 | +23.8 | -25.7 | -7.6 | +3.4 | -3.6 | +6.9 | +21.1 | +24.6 | -59.4 |
| 2026 | +0.4 | -2.7 | +3.6 | -1.0 | +1.7 | +6.6 | +3.5 | +18.9 | -8.5 | +3.0 | -29.0 |



